CirCode Biomed secured FDA authorization to start a U.S. clinical trial of its circular RNA therapeutic platform, the company told Endpoints News. The clearance allows the China‑based startup to translate its circular RNA (circRNA) constructs into first‑in‑human testing in the U.S., marking one of the earliest regulatory greenlights for this modality outside China. Circular RNAs are engineered, covalently closed RNA molecules designed to encode proteins with enhanced stability compared with linear mRNA; regulators will watch safety and manufacturability closely as circRNA moves into clinical development.